A biochemical definition of cure after brachytherapy for prostate cancer

Crook, Juanita; Tang, Chad; Thames, Howard D.; Blanchard, Pierre; Sanders, Jeremiah; Ciezki, Jay P.; Keyes, Mira; Morris, William; Merrick, Gregory S.; Catton, Charles; Raziee, Hamid; Stock, Richard G.; Sullivan, Frank; Anscher, M.S.; Millar, Jeremy; Frank, Steven J.

doi:10.1016/j.radonc.2020.04.038

Cited by 52 publications

(43 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSA kinetics has proven to be an important factor to predict biochemical control and cure after brachytherapy [ 11 , 19 , 20 , 21 , 22 , 23 , 24 ]. Helou et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control

Mayrata¹,

Espinosa²,

Büchser³

et al. 2021

jcb

View full text Add to dashboard Cite

Purpose To evaluate toxicity, prostate-specific antigen (PSA) kinetics, and cancer control of high-dose-rate brachytherapy (HDR-BT) as a salvage modality for men with locally recurrent prostate cancer, after primary HDR-BT failure. Material and methods Twelve patients with biochemical failure and a local relapse after 19 Gy single-fraction high-dose-rate brachytherapy (HDR-BT 19 Gy) were salvaged using two HDR-BT fractions. Salvage treatment consisted of two HDR-BT applications, one week apart, delivering 12 Gy to the prostate per application (HDR-BT 12 × 2). Results Median age and initial PSA prior to rescue treatment were 74 years (range, 65-80) and 5.29 ng/ml (range, 2.37-16.40), respectively. Forty-two percent had a low-risk and 58% presented with intermediate-risk prostate cancer. Median follow-up period was 26 months (range, 10-42). Median time to PSA nadir was 12 months, with a median value of 0.21 ng/ml. Most of the patients (11 of 12) achieved a PSA decline ≥ 90%. Acute grade 2 genitourinary (GU) toxicity occurred in 4 patients (33.3%) and none presented with acute gastrointestinal (GI) toxicity. Two patients (16.7%) suffered from late GU grade 2 toxicity. No grade 3 toxicity were recorded. To date, 2 patients (16.7%) have experienced biochemical failure after salvage treatment. Conclusions Salvage HDR-BT 12 × 2 is a feasible and well-tolerated treatment, with acceptable toxicity rates for men with locally recurrent prostate cancer, who failed after HDR-BT with 19 Gy. Moreover, PSA kinetics and cancer control after salvage treatment suggest that this strategy might be efficacious in this clinical setting.

show abstract

“…PSA kinetics has proven to be an important factor to predict biochemical control and cure after brachytherapy [ 11 , 19 , 20 , 21 , 22 , 23 , 24 ]. Helou et al .…”

Section: Discussionmentioning

confidence: 99%

“…They found that patients who achieved a PSA ≤ 0.2 ng/ml at 3.5-4.5 years had a probability of being free of clinical failure at 10 years with 98.7% and at 15 years with 96.1%. Moreover, for patients with PSA > 0.2 but ≤ 0.5 ng/ml, the probability of being disease-free decreased but remained high at 93.5% at 10 years [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control

Mayrata¹,

Espinosa²,

Büchser³

et al. 2021

jcb

View full text Add to dashboard Cite

show abstract

“…Crook et al 56 reported data from 7 institutions for 14,220 patients with localized prostate cancer treated with LDR brachytherapy as single or combined modality. For patients with 4-year PSA ≤ 0.2 ng/mL, the freedom-from-recurrence rates were 98.7% at 10 years and 96.1% at 15 years.…”

Section: Psamentioning

confidence: 99%

“…For patients with 4-year PSA ≤ 0.2 ng/mL, the freedom-from-recurrence rates were 98.7% at 10 years and 96.1% at 15 years. 56 …”

Section: Psamentioning

confidence: 99%

Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer

Nasser

Klein

Agbarya

2021

Advances in Radiation Oncology

View full text Add to dashboard Cite

The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.

show abstract

“…Long-term remission, and likely cure, of clinically localized prostate cancer is considered when there is no evidence of prostate-specific antigen (PSA) or radiographic progression 10 years after initial localized therapy. 1 The PSA level thresholds to define the posttreatment (biochemical) progression differ based on the mechanism of action of a surgical or radiotherapeutic approach, making cross-…”

Section: Low-dose-rate Prostate Brachytherapy (Ldr-pb) Adopts Postsurmentioning

confidence: 99%

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure

et al. 2020

View full text Add to dashboard Cite

show abstract

A biochemical definition of cure after brachytherapy for prostate cancer

Cited by 52 publications

References 22 publications

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control

Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure

Contact Info

Product

Resources

About